AI Forecasting Tools Help Drug Makers Avert Medicine Shortages

Nearly one in five Americans have faced delays obtaining critical prescriptions or medical products, according to National Institutes of Health data. Pharmaceutical companies are now deploying artificial intelligence systems to predict and prevent these shortages before they impact patient care.

The technology functions as an early-warning system, connecting disparate data sources to identify which medications face supply risks. Rather than reacting after drugs disappear from pharmacy shelves, AI models flag vulnerabilities in the production and distribution pipeline while manufacturers still have time to respond.

How prediction models work

Machine learning algorithms analyze historical demand patterns alongside emerging signals to forecast where consumption may spike. "By analyzing historical demand alongside emerging trends and other signals, AI can help predict where and when demand may increase, giving manufacturers more time to adjust production, inventory and distribution before a potential shortage becomes a crisis," explains Kirk Wroblewski, Chief Information Officer at ProPharma, a Raleigh-based pharmaceutical services company.

The systems continuously scan for external disruptions including trade bottlenecks, severe weather events, and geopolitical tensions that could interrupt supply chains. This allows drug makers to proactively reroute logistics before problems cascade into shortages.

Because pharmaceutical production planning relies on data from previous years, AI forecasting helps companies align output with actual patient needs rather than outdated projections. "Much of the shortages are linked to economics, and so AI helps with better forecasting," notes Carolina Milanesi, president and principal analyst at Creative Strategies.

Factory monitoring and waste reduction

Beyond demand forecasting, AI monitors manufacturing facilities to anticipate equipment failures, detect packaging defects, and flag potential contamination before products ship. Automated inventory systems can identify and reroute medications nearing expiration to areas where they're needed, reducing pharmaceutical waste by up to 30 percent according to National Library of Medicine research.

When paired with Internet of Things sensors, AI tracks temperature-sensitive medications during transport. Exposure to extreme conditions can degrade drug effectiveness or render medications unsafe, creating both patient safety risks and substantial financial losses for manufacturers.

The technology also accelerates regulatory compliance. When manufacturers need to modify production processes, facilities, or supplier relationships, teams must review extensive documentation before proceeding. AI systems can process these materials faster than manual review, shortening response times when supply chain adjustments become necessary.

Why it matters

Drug shortages force physicians to prescribe less effective alternatives, increase medication error risks, and can lead to worse patient outcomes or higher mortality rates. AI forecasting represents a shift from reactive crisis management to proactive supply chain resilience in an industry where delays have direct health consequences. The approach proved particularly valuable during COVID-19, when epidemiological trend analysis helped companies and governments dynamically redistribute inventory to outbreak zones.

Balancing automation with oversight

Pharmaceutical companies operate under strict regulatory frameworks where errors carry significant consequences. Industry leaders emphasize that AI supports rather than replaces human decision-making in supply chain management.

"Companies need to understand how a technology works, what data it is using, how that data is protected, and how its outputs are validated," Wroblewski says. Milanesi suggests tuning models to slightly overforecast demand, which creates buffer inventory that limits both revenue loss and patient impact from potential underprediction.

These details were first reported by Marc Saltzman for USA TODAY.